# Vera J. Suman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vera-j-suman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,420 |
| Field | Breast Cancer Treatment Studies |
| h-index | 78 |
| i10-index | 239 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5082661564 |
| ORCID iD | https://orcid.org/0000-0002-9640-5189 |
| Works | 483 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Whole-genome analysis informs breast cancer response to aromatase inhibition](https://scholariq.org/papers/whole-genome-analysis-informs-breast-cancer-response-to-aromatase-inhibition/)
- [Benign Breast Disease and the Risk of Breast Cancer](https://scholariq.org/papers/benign-breast-disease-and-the-risk-of-breast-cancer/)
- [Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials](https://scholariq.org/papers/meta-analysis-of-phase-ii-cooperative-group-trials-in-metastatic-stage-iv/)
- [Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031](https://scholariq.org/papers/randomized-phase-ii-neoadjuvant-comparison-between-letrozole-anastrozole-and/)
- [Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study](https://scholariq.org/papers/efficacy-of-pazopanib-in-progressive-radioiodine-refractory-metastatic/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine](https://scholariq.org/papers/dna-methyltransferase-expression-in-triple-negative-breast-cancer-predicts/)
- [Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials](https://scholariq.org/papers/anthracycline-containing-and-taxane-containing-chemotherapy-for-early-stage/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.